importantSYS.SOURCE: X• 2026-08-19T13:33:35Z
Moderna Reports First Positive Phase 3 Results for Individualized mRNA Neoantigen Therapy in Melanoma
Moderna and Merck reported positive Phase 3 results for intismeran autogene, an individualized mRNA neoantigen therapy for melanoma, in combination with KEYTRUDA, meeting primary and secondary endpoints. This marks the first positive Phase 3 outcome for an mRNA-based cancer therapy and an individualized neoantigen approach.
*** END OF TRANSMISSION ***